膀胱癌患者SUB-尿路上皮下注射度伐利尤单抗1(SUBDUE-1)试验:首次人体试验
SUBDUE-1是一项在膀胱癌患者中开展的首次人体、Ib期3+3剂量递增试验,评估根治性膀胱切除术前至少2周于尿路上皮下注射度伐利尤单抗(25、75、150 mg)的安全性及对组织和循环免疫细胞的影响。共纳入11例患者,未发生免疫相关不良事件及4/5级不良事件,注射后组织免疫细胞群体发生变化。
要点
- 尿路上皮下注射度伐利尤单抗可行且安全,未出现免疫相关不良事件。
- 共报告14例不良事件(10例1级、3例2级、1例3级),无4级或5级事件。
- 注射后组织免疫细胞群体发生变化(P=0.012),25-150 mg剂量组M2巨噬细胞(CD163)显著增加(P=0.021)。
核心结论
- 尿路上皮下注射度伐利尤单抗可行且安全,无免疫相关不良事件,并显示出局部免疫学效应。
研究设计与样本
- Ib期3+3剂量递增首次人体试验,纳入化疗和免疫治疗初治(允许卡介苗)的非转移性肌层浸润性膀胱癌或拟行根治性膀胱切除术的非肌层浸润性膀胱癌患者。
- 于根治性膀胱切除术前至少2周在25个部位(25×1 mL注射)注射度伐利尤单抗,预设三个剂量(25、75、150 mg)稀释于25 mL生理盐水。
主要发现
- 共招募11例患者(10例男性,1例女性)。
- 美国泌尿协会症状评分或O'Leary间质性膀胱炎量表未报告显著变化。
- 共报告14例不良事件(10例1级、3例2级、1例3级),均不被认为与免疫相关;未记录到4级或5级不良事件。
- 所有患者均接受了根治性膀胱切除术。
- 注射度伐利尤单抗后组织免疫细胞群体发生变化(P=0.012),比较25-150 mg剂量时M2巨噬细胞(CD163)有统计学显著增加(P=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations. PATIENTS AND METHODS: The patients were chemotherapy and immunotherapy naïve (bacille Calmette-Guérin allowed) with non-metastatic muscle-invasive bladder cancer or non-muscle-invasive bladder cancer planned for radical cystectomy (RC). The study was a Phase Ib 3 + 3 dose-escalation design with sub-urothelial injection of durvalumab at three pre-determined doses (25, 75, 150 mg) diluted in 25 mL normal saline, injected at 25 locations (25 × 1 mL injections), at least 2 weeks before RC. RESULTS: A total of 11 patients were recruited (10 male, one female). No significant changes were reported on American Urological Association Symptom Score or O'Leary Interstitial Cystitis Scale. In all, 14 adverse events (AEs) were reported (10 Grade 1, three Grade 2, one Grade 3), none considered immune-related. No Grade 4 or 5 AEs were recorded. All the patients underwent RC. Tissue immune populations changed following durvalumab injection (P = 0.012), with a statistically significant increase in M2-macrophage (CD163) when comparing the 25-150 mg dose (P = 0.021). Basal/mixed cancers showed a larger CD163 increase than luminal cancers (P = 0.033). CONCLUSION: Sub-urothelial injection of durvalumab is feasible and safe without immune-related AEs and shows local immunological effects.
引用
- Hayne D, Ong K, Swarbrick N, et al. The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer. BJU Int. 2024. PMID: 38469652. doi:10.1111/bju.16325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。